Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer

Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery

(2014) E Sim et al.   BRITISH JOURNAL OF PHARMACOLOGY

MicroRNA Array Analysis Finds Elevated Serum miR-1290 Accurately Distinguishes Patients with Low-Stage Pancreatic Cancer from Healthy and Disease Controls

(2013) A. Li et al.   CLINICAL CANCER RESEARCH

Up-regulation of microRNA-1290 impairs cytokinesis and affects the reprogramming of colon cancer cells

(2012) Jia Wu et al.   CANCER LETTERS

miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer

(2012) Yumi Endo et al.   ENDOCRINE-RELATED CANCER

RNAi-Mediated Knock-Down of Arylamine N-acetyltransferase-1 Expression Induces E-cadherin Up-Regulation and Cell-Cell Contact Growth Inhibition

(2011) Jacky M. Tiang et al.   PLoS One

MicroRNAs in Renal Cell Carcinoma: Diagnostic Implications of Serum miR-1233 Levels

(2011) Lena M. Wulfken et al.   PLoS One

Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells

(2010) Jacky M. Tiang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues

(2010) Sun Jung Kim et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

miR-206 Expression Is Down-regulated in Estrogen Receptor  -Positive Human Breast Cancer

(2008) N. Kondo et al.   CANCER RESEARCH

Arylamine N-acetyltransferases: From Structure to Function

(2008) Edith Sim et al.   DRUG METABOLISM REVIEWS

ArylamineN-acetyltransferase 1 expression in breast cancer cell lines: A potential marker in estrogen receptor-positive tumors

(2007) Larissa Wakefield et al.   GENES CHROMOSOMES & CANCER